Comparative Pharmacology
Head-to-head clinical analysis: MYTREX F versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYTREX F versus SULLA.
MYTREX F vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic